• Irmina A Elliott, Amanda M Dann, Razmik Ghukasyan, Lauren Damato, Mark D Girgis, Jonathan C King, O J Hines, Howard A Reber, and Timothy R Donahue.
• Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
• HPB (Oxford). 2018 May 1; 20 (5): 418-422.

BackgroundPancreatic fistula is a major cause of morbidity after pancreas surgery. In 2014, a single-center, randomized-controlled trial found pasireotide decreased pancreatic fistula rates. However, this finding has not been validated, nor has pasireotide been widely adopted.MethodsA single-arm study in 111 consecutive patients undergoing pancreatic resection April 2015-October 2016 was conducted. Beginning immediately before surgery, patients received 900 μg subcutaneous pasireotide twice daily for up to seven days. Fistula rates were compared to 168 historical controls from July 2013 to March 2015. The primary outcome was Grade B/C fistula, as defined by the International Study Group on Pancreatic Fistula (ISGPF).ResultsThere were no significant differences between the pasireotide group and historical controls in demographics, comorbidities, operation type, malignancy, gland texture, or pancreatic duct size. Pasireotide did not reduce fistula rate (15.5% control versus 17.1% pasireotide, p = 0.72). In subgroup analyses of pancreaticoduodenectomy or distal pancreatectomy, or patients with soft gland texture and/or small duct size, there was no decrease in fistulas. Thirty-nine patients (38%) experienced dose-limiting nausea.ConclusionsIn an appropriately-powered, single-institution prospective study, pasireotide was not validated as a preventive measure for pancreatic fistula.Copyright © 2017 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

7 keywords...

hide…